MA54070A - Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique - Google Patents

Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique

Info

Publication number
MA54070A
MA54070A MA054070A MA54070A MA54070A MA 54070 A MA54070 A MA 54070A MA 054070 A MA054070 A MA 054070A MA 54070 A MA54070 A MA 54070A MA 54070 A MA54070 A MA 54070A
Authority
MA
Morocco
Prior art keywords
humanized
variants
stabilized
blood
brain barrier
Prior art date
Application number
MA054070A
Other languages
English (en)
Inventor
Thomas O Cameron
Graham K Farrington
Arsalan S Haqqani
Andreas Lehmann
Nels E Pederson
R Blake Pepinsky
Gopalan Raghunathan
Benjamin A Smith
Danica Stanimirovic
Traian Sulea
Dingyi Wen
Original Assignee
Biogen Ma Inc
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Nat Res Council Canada filed Critical Biogen Ma Inc
Publication of MA54070A publication Critical patent/MA54070A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
MA054070A 2018-10-29 2019-10-28 Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique MA54070A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862751962P 2018-10-29 2018-10-29

Publications (1)

Publication Number Publication Date
MA54070A true MA54070A (fr) 2021-09-08

Family

ID=68582454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054070A MA54070A (fr) 2018-10-29 2019-10-28 Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique

Country Status (13)

Country Link
US (1) US20220089704A1 (fr)
EP (1) EP3873934A2 (fr)
JP (1) JP2022509372A (fr)
KR (1) KR20210111242A (fr)
CN (1) CN113508135A (fr)
AU (1) AU2019371814A1 (fr)
BR (1) BR112021008105A2 (fr)
CA (1) CA3117409A1 (fr)
EA (1) EA202191179A1 (fr)
IL (1) IL282677A (fr)
MA (1) MA54070A (fr)
MX (1) MX2021004772A (fr)
WO (1) WO2020092202A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230272052A1 (en) * 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2545539A1 (fr) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
HUE030701T2 (hu) 2005-05-27 2017-05-29 Biogen Ma Inc Tweak-kötõ antitestek
SI3308788T1 (sl) 2005-06-23 2019-01-31 Biogen Ma Inc. Sestave in metode za modulacijo združevanja SMN2
WO2007025385A1 (fr) 2005-08-31 2007-03-08 Universite Laval Anticorps et leur utilisation dans le traitement, la prevention et le diagnostic d'une maladie associee a des anomalies de sod1
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EA017611B1 (ru) 2007-01-05 2013-01-30 Юнивэсэти Оф Цюрих Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела или его связывающего фрагмента или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), антиген, полинуклеотид, вектор и клетка-хозяин, их включающие композиция и набор и способ диагностики или лечения неврологических расстройств посредством
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CA2729961C (fr) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Anticorps anti-lingo, li113, li62 variant co2
EP3521309A1 (fr) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Anticorps humains anti-alpha-synucléine
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
PT2393828T (pt) 2009-02-03 2017-01-18 Amunix Operating Inc Polipéptidos recombinantes estendidos e composições que compreendem os mesmos
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
NZ596787A (en) 2009-06-08 2014-03-28 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
SI3305302T1 (sl) 2009-06-17 2018-12-31 Biogen Ma Inc. Sestave in metode za modulacijo združevanja smn2 pri subjektu
JP5813641B2 (ja) 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
WO2011028344A2 (fr) 2009-08-25 2011-03-10 Amunix Operating Inc. Compositions d'antagonistes des récepteurs d'interleukine-1 et leurs procédés de préparation et d'utilisation
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
CN102781960B (zh) 2010-02-16 2014-12-10 米迪缪尼有限公司 Hsa相关组合物及使用方法
BR112012022102A2 (pt) * 2010-03-03 2017-01-10 Boehringer Ingelheim Int polipeptídeos de ligação a a-beta.
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
ES2686550T3 (es) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
EP2651979B1 (fr) 2010-12-17 2019-08-28 Neurimmune Holding AG Anticorps anti-sod1 humains
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
GB2491006A (en) 2011-05-05 2012-11-21 Novozymes Biopharma Uk Ltd Albumin variants
TR201815563T4 (tr) 2011-06-23 2018-11-21 Biogen Int Neuroscience Gmbh Anti-alfa sinüklein bağlayıcı moleküller.
PL2766397T3 (pl) 2011-10-11 2018-10-31 F.Hoffmann-La Roche Ag Ulepszone składanie przeciwciał bispecyficznych
ES2883212T3 (es) 2011-10-28 2021-12-07 Biogen Int Neuroscience Gmbh Moléculas de unión específica a TDP-43
LT2802606T (lt) * 2012-01-10 2018-10-10 Biogen Ma Inc. Terapinių molekulių transporto per kraujo-smegenų barjerą padidinimas
US10172953B2 (en) 2012-02-27 2019-01-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
MX2015008024A (es) 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Anticuerpos anti-tau humanos.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2956002B1 (fr) 2013-02-16 2017-09-06 Albumedix A/S Modèle pharmacocinétique animal
US20160052993A1 (en) 2013-05-03 2016-02-25 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
IL278941B (en) 2014-09-30 2022-07-01 Neurimmune Holding Ag dprs antibodies which originate in the human body
US10184008B2 (en) * 2014-12-19 2019-01-22 Medimmune Limited Blood brain barrier transport molecules and uses thereof
US10654917B2 (en) * 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
CN108601830B (zh) 2015-12-18 2023-02-03 比奥根Ma公司 双特异性抗体平台
US10738115B2 (en) * 2016-07-06 2020-08-11 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
WO2018109663A1 (fr) * 2016-12-12 2018-06-21 National Research Council Of Canada Variants d'anticorps franchissant la barrière hémato-encéphalique et leurs utilisations
CA3052058A1 (fr) * 2017-01-30 2018-08-02 National Research Council Of Canada Agents de migration a travers la barriere hemato-encephalique et utilisations associees

Also Published As

Publication number Publication date
MX2021004772A (es) 2021-08-16
US20220089704A1 (en) 2022-03-24
AU2019371814A1 (en) 2021-06-17
WO2020092202A2 (fr) 2020-05-07
IL282677A (en) 2021-06-30
EA202191179A1 (ru) 2021-09-09
KR20210111242A (ko) 2021-09-10
JP2022509372A (ja) 2022-01-20
EP3873934A2 (fr) 2021-09-08
CA3117409A1 (fr) 2020-05-07
BR112021008105A2 (pt) 2021-08-03
WO2020092202A3 (fr) 2020-07-23
WO2020092202A9 (fr) 2021-05-14
CN113508135A (zh) 2021-10-15

Similar Documents

Publication Publication Date Title
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
GB2591408B (en) Motion graph construction and lane level route planning
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA54070A (fr) Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
MA49152A (fr) Schémas posologiques d'immunoconjugués anti-cd33
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
MA52148A (fr) Peptides chimères pour administration d'antisens
MA54571A (fr) Dispositif d'injection
FR3025533B1 (fr) Installation anti-bruit pour voie de transport guide et voie de transport guide equipee d'une telle installation
UA42018S (uk) Вмістина «бінбег»
UA41097S (uk) Стіна-бар'єр для спортивного майданчика
UA40211S (uk) М'який контейнер для насипних вантажів
UA42900S (uk) Упаковка «равлик боб 9»
UA42902S (uk) Упаковка «равлик боб 11»
UA42365S (uk) Будівельна планка для парканів та огорож
MA54682A (fr) L-triiodothyronine (t3) destinée à être utilisée pour limiter l'obstruction microvasculaire
UA41001S (uk) Пляшка «buvette»
UA39966S (uk) Будівельна планка для парканів та огорож
UA39967S (uk) Будівельна планка для парканів та огорож
MA53225A (fr) Agents inhibiteurs d'ask1
FR3069872B1 (fr) Dispositif pour tendre une matiere d'une tente
GB201911707D0 (en) The "Pushy"
MA52357A (fr) Tuyau d'irrigation
MA54570A (fr) Dispositif d'injection
UA42179S (uk) Малюнок для опаковання «start мюслі»